[1]
Long, G.V., Hauschild, A., Santinami, M., Atkinson, V., Mandala, M., Chiarion-Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., Haydon, A., Robert, C., Mortier, L., Schachter, J., Schadendorf, D., Lesimple, T., Plummer, R., Ji, R., Zhang, P., Mookerjee, B., Legos, J., Kefford, R., Drummer, R. and Kirkwood, J.M. 2018. Efficacy Outcomes in the Phase 3 COMBI-AD Study of Adjuvant Dabrafenib Plus Trametinib vs Placebo in Patients with Stage III BRAFV600E/K-Mutant Melanoma. SKIN The Journal of Cutaneous Medicine. 2, S1 (Feb. 2018), S43. DOI:https://doi.org/10.25251/skin.2.supp.43.